A rapid quantitative microtest for live, attenuated rabies vaccine.

Area of Science:

• Veterinary immunology
• Vaccine development
• Diagnostic assay development

Background:

• Rabies vaccine potency is crucial for preventing rabies virus infection.
• Current potency testing methods, like the mouse lethal dose 50 (M-LD50) test, can be time-consuming and complex.
• Standardized and efficient methods are needed for quality control during vaccine production.

Purpose of the Study:

• To develop and validate a rapid fluorescent antigen test (RFAT) for quantitative potency evaluation of live attenuated rabies vaccine (ERA strain).
• To compare the performance of the RFAT with the established M-LD50 test for rabies vaccine potency assessment.
• To assess the suitability of RFAT for routine use in vaccine manufacturing.

Main Methods:

• Development of a microplate-based rapid fluorescent antigen test (RFAT).
• The RFAT is based on the principles of the rapid fluorescent focus inhibition test (RFFIT).
• Parallel testing of bulk rabies vaccine (ERA strain) samples using both RFAT and M-LD50 assays.

Main Results:

• The RFAT demonstrated comparable sensitivity to the traditional M-LD50 test for rabies vaccine potency evaluation.
• The RFAT offers significant advantages in terms of simplicity and speed compared to the M-LD50 test.
• The developed RFAT is suitable for quantitative potency assessment during various stages of vaccine manufacture.

Conclusions:

• The rapid fluorescent antigen test (RFAT) provides a reliable and efficient alternative for rabies vaccine potency testing.
• Implementing RFAT can streamline vaccine manufacturing processes, leading to improved quality control and potentially faster vaccine availability.
• This assay simplifies the quantitative evaluation of live attenuated rabies vaccines, supporting robust vaccine production.